Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT03872232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03872232
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03872232. Randomized; quadruple masking; primary purpose treatment. Start 2019-02-26 (actual); primary completion 2020-08-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
Condition
Hypercholesterolemia
Condition
Hypertension
Intervention (Drug)
Ezetimibe/Rosuvastatin
Intervention (Drug)
Telmisartan
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct03872232
Content hash
0ae3c78fb894cbf2ff912e50a93f682442e62093d0d72506b41dd0b6a2d25768